Loading clinical trials...
Loading clinical trials...
Dose-Finding Run-in Phase I Followed by a Phase III, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations
Conditions
Interventions
chemotherapy (Mitoxantrone, Cytarabine)
Placebo
+2 more
Locations
1
Germany
Ulm University Hospital
Ulm, Germany
Start Date
November 17, 2016
Primary Completion Date
March 9, 2020
Completion Date
March 9, 2020
Last Updated
October 6, 2021
NCT05564390
NCT07320235
NCT06782542
NCT05886049
NCT07295951
NCT06284486
Lead Sponsor
University of Ulm
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions